We have evaluated the effect of a colloid solution on acute kidney injury in paediatric cardiac surgery. A total of 195 patients were ramdomly divided into an hydroxyethyl starch group and a control group. In the starch group, 6% hydroxyethyl starch 130/0.4 (Volulyte â ) was used as the primary fluid for volume resuscitation but was limited to 30 ml.kg À1 . In the control group, only crystalloid fluid was used during the peri-operative period. The incidence of acute kidney injury, peri-operative transfusion, clinical outcomes and laboratory data were compared. The incidence of acute kidney injury determined by Paediatric Risk, Injury, Failure, Loss, End-stage renal disease (pRIFLE) and Acute Kidney Injury Network (AKIN) criteria were no different between the two groups (starch group 40.8% vs. control group 30.0%; p = 0.150 using pRIFLE; 19.6% vs. 21.1% respectively, p = 0.602 using AKIN). There were no differences in clinical outcomes such as mortality, major adverse events, intensive care unit stay or duration of mechanical ventilation. Clotting time as measured using rotational thromboelastometry (ROTEM) was prolonged, and clot firmness after 10 min and maximal clot firmness were shorter in the starch group compared with the control group after sternal closure. There was no difference in transfusion between the two groups. Patients with acute kidney injury had worse clinical courses than those without acute kidney injury. We conclude that intra-operative use of 6% hydroxyethyl starch 130/0.4 up to 30 ml.kg À1 was not associated with postoperative acute kidney injury in paediatric cardiac patients.
Introduction
Colloid solutions are used for volume resuscitation in order to maintain intravascular volume and reduce transfusion requirements. However, previous studies have questioned the efficacy and safety of colloids [1] [2] [3] . In critically ill adults, hydroxyethyl starch (HES) 130/0.42 has been associated with acute kidney injury (AKI) and an increased requirement for renal replacement therapy [2, 4] . The Surviving Sepsis Campaign guidelines recommend crystalloid solutions for initial resuscitation rather than HES [5] . However in one study, critically ill patients who received colloids, including gelatin, dextrans, HES and albumin for resuscitation demonstrated a lower 90-day mortality compared with those who received crystalloids [6] . Additionally, it is unclear whether HES is harmful if limited to peri-operative use [7] . More evidence is required to determine the peri-operative effect of colloids in hypovolaemic patients and there are limited data regarding intra-operative use in children.
Recent advances in surgical techniques and anaesthetic care have improved outcomes in children with congenital heart disease. However, the incidence of postoperative AKI is between 27% and 50% [8] [9] [10] , with a 20-79% mortality [11] . Known AKI risk factors after paediatric cardiac surgery are: young age; surgical complexity; prolonged cardiopulmonary bypass times; and reduced pre-operative haemoglobin level [11, 12] . Data regarding the effect of a new colloid solution, 6% HES 130/0.4 (Volulyte â , Fresenius Kabi GmbH, Bad
Homgurg, Germany) on AKI after paediatric cardiac surgery are limited. We decided to determine whether there was an association between intra-operative HES 130/0.4 and postoperative AKI in paediatric cardiac patients. We also wanted to compare the effect of HES 130/0.4 with crystalloid on blood loss and other clinical outcomes.
Methods
Following local research ethics committee approval, children aged less than seven years, of ASA physical status 1-3, undergoing cardiac surgery with cardiopulmonary bypass between November 2015 and November 2016, were enrolled. The day before surgery, a staff member met with each child's parent or guardian, explained the study protocol and obtained written informed consent. Exclusion criteria were: pre-operative creatinine values exceeding 88.4 lmol.l
À1
, a history of renal replacement therapy; liver function abnormality (aspartate transaminase > 40 units.l
, alanine aminotransferase > 40 units.l À1 ); diabetes mellitus; allergy; or coagulation disorder (platelets < 150,000 mm À3 , prothrombin time > 70% of control, activated partial thromboplastin time > 45 s, fibrinogen < 100 mg.l
). Patients were randomly allocated to one of two groups, HES or control group in a ratio of 1:1. A stratified randomisation assignment was used to create group assignment for surgical complexity-based subgroup analysis. The surgery was categorised using Risk Adjustment for Congenital Heart Surgery (RACHS) [13] . Random allocation sequence was performed by a research assistant who prepared coded and sealed opaque envelopes. The assistant opened each envelope after patient enrolment.
Patients were monitored according to the Association of Anaesthetists of Great Britain and Ireland (AAGBI) guidelines [14] ; CJ, Seoul, Korea) was infused when additional intravascular volume expansion was required. In the control group crystalloid only was used. The volume of crystalloid added to the pump prime was determined by the bypass circuit volume and haematocrit. After sternotomy, and following venous and aortic cannulation, heparin 300 units.kg
was administered in order to achieve an activated clotting time of 450 s. Cardiopulmonary bypass was instituted using non-pulsatile flow and varying degrees of hypothermia depending on the surgical procedure. An haematocrit of 25-28% was maintained during bypass and blood was added if necessary. Bypass flow rate was maintained at 120-170 ml.kg
Transfusion criteria were the same in both groups; packed red cells were transfused when the haemoglobin was < 80 g.l À1 in non-cyanotic children and Heparin reversal was confirmed using the activated clotting time.
EXTEM and FIBTEM were measured at two timepoints for each patient: after protamine infusion; and following sternal closure. Postoperatively, patients were transferred to the paediatric intensive care unit and their lungs were mechanically ventilated. Postoperative fluids were given according to local policy. Laboratory data, transfusion amount, volume expansion, urine output and blood loss were evaluated up to postoperative day seven. Intra-operative and postoperative vaso-active inotropic scores were calculated as follows: dopamine dose (lg.kg ) + 100 9 noradrenaline dose (lg.kg
. min À1 ) [15] . The primary outcome was the incidence of AKI after cardiac surgery. We used Paediatric Risk, Injury, Failure, Loss, End-stage renal disease (pRIFLE) criteria [16] and Acute Kidney Injury Network (AKIN) classifications [17] . The pRIFLE classifications are as follows: risk, estimated glomerular filtration rate (eGFR) decreased by 24%; injury, eGFR decreased by 50%; failure, eGFR decreased by 75% or eGFR < 35 ml.min Clinical outcomes including major adverse events, duration of mechanical ventilation of the lungs, length of intensive care unit (ICU) and hospital stay, and mortality, were assessed and compared between the groups. Major adverse events were defined as: cardiac arrest; re-sternotomy due to haemodynamic instability; extracorporeal membrane oxygenation support; significant arrhythmia requiring treatment; cerebral haemorrhage or infarct; and pulmonary complications.
The sample size was calculated for the analysis of binary outcome for a non-inferior test. According to previous studies, the incidence of AKI after paediatric cardiac surgery varies between 9% and 42% [9, 19, 20] . Therefore, we assumed that the incidence of AKI would be 15% in both the HES and the control groups. An equivalence margin (non-inferiority limit) was defined as 13%. We set a power of 0.8 and a type-1 error of 0.05 for the non-inferiority test. The required sample size was 94 patients per group and we decided to include 200 patients in order to allow for a dropout rate of 8%.
Data normality was tested using the KolmogorovSmirnov test. The Chi-square test was used to test categorical data significance, and Fisher's exact test was used when > 20% of the cells had expected counts less than five. Student's t-test or the Mann-Whitney ranksum test was used to compare continuous data. All data were analysed using SPSS for Windows (version 21.0; SPSS, Inc., Chicago, IL, USA) software and a p value < 0.05 was considered statistically significant.
Results
Two hundred patients were randomly allocated to one or other group. The data for five patients, two in the HES group and three in the control group, were excluded from analysis and the data from the remaining 195 patients were analysed (Fig. 1) . Baseline patient characteristics and intra-operative data are shown in Tables 1 and 2 respectively. There were no significant differences in pre-operative laboratory data, bypss duration or anaesthesia duration between the groups. Mean (SD) intra-operative urine output was 22.6 (14.3) ml.kg The ROTEM data demonstrated differences in coagulation profiles between the groups. The EXTEM clotting time was higher in the HES group compared with the control group following protamine administration and lower after sternal closure (Table 3 ). The FIBTEM MCF was lower after sternal closure in the HES group compared with the control group. Total intra-operative transfusion volumes were the same for both groups. Table 4 shows the postoperative values and clinical outcomes. Acute kidney injury incidences assessed using pRIFLE and AKIN classifications were 35.9% and 21.5%, respectively. Most patients had low-grade AKI; there was no difference between the groups in terms of AKI incidence with either classification. There were also no differences between the groups in terms of postoperative transfusion, laboratory data, duration of mechanical ventilation of the lungs, length of ICU or total hospital stay, and mortality. Table 5 shows the clinical outcome comparisons between patients with and without AKI. When AKI occurred and was evaluated using pRIFLE criteria, children with AKI had prolonged mechanical ventilation and ICU and hospital stay compared with those without AKI. The incidence of major adverse events was significantly higher in children with AKI compared with those without. When AKI was assessed using the AKIN classification, there were no differences in the duration of mechanical ventilation or ICU and hospital stay between the two groups. However, the incidence of major adverse events was higher in patients with AKI compared with those without.
Discussion
We found that intra-operative administration of 6% HES 130/0.4 in a volume of up to 30 ml.kg À1 did not increase the incidence of postoperative AKI in children following cardiac surgery employing bypass and that intra-operative and postoperative transfusions were the same for both groups. Acute kidney injury in children is common following cardiac surgery, with a reported incidence of between 27% and 50% [8, 9, 21] . One major factor inducing kidney injury during cardiac surgery is bypass-related renal ischaemia. During bypass, renal vasoconstriction combined with haemodilution decreases oxygen delivery to the kidneys; further impairment occurs due to increased renal oxygen consumption, as well as possible embolisation after weaning from bypass [22, 23] . Haemodilution during bypass can result in decreased oncotic pressure and interstitial oedema; this is compounded when large fluid volumes are administered in order to maintain intravascular volume. The purpose of colloid administration is to maintain osmotic pressure and avoid interstitial fluid retention [22] . Rex et al. studied adults undergoing mitral valve replacement and found that 4% albumin added to the pump prime volume significantly increased total blood volume and reduced extravascular fluid compared with Ringer's lactate [24] . However, there are concerns regarding renal function following colloid administration. Two large randomised trials revealed negative effects of colloid administration in adult intensive care patients; 6% HES 130/0. [2, 3] . However, these studies only included critically ill adults. With regard to cardiac surgical patients, the safety of colloid infusions has been questioned. In a retrospective study, adults who received 6% HES 130/0.4 were twice as likely to develop postoperative AKI and RACHS, Risk Adjustment for Congenital Heart Surgery; GFR, glomerular filtration rate; PT-INR, prothrombin time-international normalised ratio; aPTT, activated partial thromboplastin time.
they produced reduced urine output compared with those given crystalloids [25] . However, in one prospective multi-centre cohort study, peri-operative use of 6% HES 130/0.4 for cardiac surgery did not increase the risk of renal replacement therapy (OR 0.99) [26] . Rather, the non-HES group required more intra-operative vasopressors and had longer bypass times [26] . Few studies have assessed colloid solution efficacy and safety in children. Sumpelmann et al. evaluated 6% HES 130/0.42 in major paediatric surgery [27] . The mean (SD) infused HES volume was 10.6 (5.8) ml.kg À1 and no serious complications, such as renal failure, were observed [27] . In neonates, volume expansion with 6% HES 200/0.5 up to 10 ml.kg À1 did not increase serum creatinine levels [28] . Hanart et al. compared albumin with 6% HES 130/0.4 in paediatric cardiac surgical patients; the effects on renal function were comparable and there was a reduction in allogeneic transfusion [29] . However, no previous study has compared 6% HES 130/0.4 with crystalloid in terms of renal function in large numbers of paediatric patients undergoing cardiac surgery.
Several factors should be considered when interpreting our results. Firstly, the infusion volume was limited to 30 ml.kg
À1
; the mean infusion volume was approximately 14 ml.kg À1 (range 2.0-29.9 ml.kg À1 ) and some patients only received small volumes of HES. Secondly, we used 6% HES 130/0.4 in a balanced solution and this has only recently been introduced clinically. Different molecular weights and degrees of substitution within HES products can elicit different effects on renal function. For example, one animal study demonstrated that 10% HES 200/0.5 induced more renal tubular damage than 6% HES 130/0.42 [30] . Finally, we excluded patients with pre-operative renal dysfunction. Our conclusions, that the effects of HES on renal function are similar to those of crystalloid, should be interpreted in the context of our specific study protocol. For renal function assessment, we used pRIFLE and AKIN criteria; both have a good correlation with AKI clinical outcomes [21] , but sensitivity in identifying AKI may differ between the two because the eGFR is used for pRIFLE, whereas serum creatinine is used for AKIN. An AKI diagnosis based on serum creatinine may be missed because it can alter depending on volume status and eGFR calculations may increase and hence reduce the apparent incidence of AKI [31] . In a previous study, the pRIFLE classification was more sensitive at detecting AKI (51.1%) than that of AKIN (37.3%) [32] and our results reflect this; patients with AKI assessed using pRIFLE showed worse clinical outcomes after cardiac surgery than those without, as has previously been demonstrated [8, 33] . Intra-operative urine output was significantly greater in the control group than in the HES group, although urine output during bypass itself did not differ significantly between the groups. Song et al. reported that urine output during bypass could predict AKI after cardiac surgery [34] and a urine output during bypass < 1.5 ml.kg
.h À1 was associated with AKI [35] . However, inflammation-triggered tubular damage during bypass can increase urine output [36] and our patients had relatively high urine outputs during surgery. A comprehensive approach is required for urine output interpretation during cardiac surgery. Fluid overload results in worse postoperative outcomes [37] . A previous report by Hazle et al. demonstrated that early fluid overload or weight gain following cardiac surgery was associated with AKI in infants [38] . A study by Van der Linden et al. concluded that 6% HES 130/0.4 was associated with less positive fluid balance, without increasing the risk of renal dysfunction, compared with human albumin solution [39] . In the present study, we measured immediate postoperative weight and found no significant difference between children who received HES and those that received crystalloid only.
Coagulation abnormality is a possible adverse effect of colloid administration. Hydroxyethyl starch 200/0.62 is known to reduce levels of von Willebrand factor [40] . Colloids inhibit blood coagulation more than crystalloids even after allowing for haemodilution [41], and any dilutional coagulopathy is thought to be caused by acquired fibrinogen deficiency or dysfunction [42] . Another study demonstrated that 30% in vivo dilution with HES 130/0.4 reduced the maximum clot firmness and activities of coagulation factors II, VII, VIII, IX, X and XIII in adults [43] . In our study, EXTEM clotting times were longer and the FIB-TEM A10 and MCF were reduced in the HES group compared with the control group. These results are similar to those of a previous report in adult patients undergoing cardiac surgery under bypass, but the differences between the groups were less in our study; patients who received HES (130/0.4) peri-operatively had lower FIBTEM MCF values (median, 7 mm vs. 13 mm in the control group) and significantly prolonged clot firmness durations (median, 185 s vs. 107 s in the control group) immediately postoperatively [44] . However, we found no significant differences in bleeding or transfusion requirements between our two groups. Two randomised controlled trials in which dextrans were compared with crystalloids found no differences in bleeding [45, 46] . Additionally, the use of 6% HES 130/0.4 as a pump prime volume of 20 ml.kg À1 or 30 ml.kg À1 per day did not increase peri-operative blood loss in adults undergoing cardiac surgery [47, 48] . We believe that although the ROTEM coagulation profiles in the HES group were abnormal compared with the control group, many patients did not meet transfusion criteria and therefore transfusion volumes did not differ between the groups. Our study has limitations. Firstly, infused HES volumes varied between patients because we set an upper limit of 30 ml.kg À1 . Secondly, we could not use urine output criteria for AKI classification based on pRIFLE because urine output measurement intervals were not constant. Finally, we did not perform ROTEM pre-operatively and therefore could not assess any changes from baseline.
In conclusion, the intra-operative use of 6% HES 130/0.4 in paediatric cardiac surgery did not increase AKI compared with crystalloid only. The incidence of AKI was 40% and 21% according to pRIFLE and AKIN classifications, respectively, and patients with AKI showed worse clinical outcomes. Although the HES group had greater coagulopathy according to ROTEM measurements, blood loss and transfusion volumes did not differ from the control group and we believe that 6% HES 130/0.4 in a volume of up to 30 ml.kg À1 can safely be used for intravenous administration in children undergoing cardiac surgery. 
